Quantitative reverse transcriptase polymerase chain reaction and the Oncotype DX test for assessment of human epidermal growth factor receptor 2 status: Time to reflect again?

Journal of Clinical Oncology

Volumn 29, Issue 32, 2011, Pages 4219-4221

  Bartlett, John M S ^a,b   Starczynski, Jane ^a  

^a ONTARIO INSTITUTE FOR CANCER RESEARCH   (Canada)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; PHOSPHATIDYLINOSITOL 3 KINASE; RNA; TRASTUZUMAB;

BREAST CANCER; CANCER PATIENT; CHROMOSOME 17; CLINICAL ASSESSMENT; CLINICAL DECISION MAKING; COMPARATIVE GENOMIC HYBRIDIZATION; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; DIAGNOSTIC TEST ACCURACY STUDY; EDITORIAL; FLUORESCENCE IN SITU HYBRIDIZATION; GENE MUTATION; HISTOPATHOLOGY; HUMAN; IMMUNOASSAY; IMMUNOHISTOCHEMISTRY; MULTIPLEX LIGATION DEPENDENT PROBE AMPLIFICATION; ONCOTYPE DX TEST; OUTCOME ASSESSMENT; PATHOLOGIST; PATIENT CARE; PHYSICIAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUANTITATIVE ASSAY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION; SENSITIVITY AND SPECIFICITY; SIGNAL TRANSDUCTION; TREATMENT RESPONSE;

BREAST NEOPLASMS; FEMALE; HUMANS; KI-67 ANTIGEN; NEOPLASM RECURRENCE, LOCAL; QUALITY ASSURANCE, HEALTH CARE; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 81155123169     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.37.5824     Document Type: Editorial

References (16)

1. Dabbs DJ, Klein ME, Mohsin SK, et al.: High false-negative rate of HER2 quantitative reverse transcription polymerase chain reaction of the Oncotype DX test: An independent quality assurance study. J Clin Oncol 29:4279-4285, 2011
2. Baehner FL, Achacoso N, Maddala T, et al.: Human epidermal growth factor receptor 2 assessment in a case-control study: Comparison of fluorescence in situ hybridization and quantitative reverse transcription polymerase chain reaction performed by central laboratories. J Clin Oncol 28:4300-4306, 2010
3. Wolff AC, Hammond ME, Schwartz JN, et al.: American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25:118-145, 2007 (Pubitemid 350003059)
4. Cuadros M, Talavera P, López FJ, et al.: Real-time RT-PCR analysis for evaluating the HER2/neu status in breast cancer. Pathobiology 77:38-45, 2010
5. Nistor A, Watson PH, Pettigrew N, et al.: Real-time PCR complements immunohistochemistry in the determination of HER-2/neu status in breast cancer. BMC Clin Pathol 6:2, 2006
6. Susini T, Bussani C, Marini G, et al.: Preoperative assessment of HER-2/neu status in breast carcinoma: The role of quantitative real-time PCR on core-biopsy specimens. Gynecol Oncol 116:234-239, 2010
7. Lehmann-Che J, Amira-Bouhidel F, Turpin E, et al.: Immunohistochemical and molecular analysis of HER2 status in breast cancers are highly concordant and complementary approaches. Br J Cancer 104:1739-1746, 2011
8. Noske A, Loibl S, Darb-Esfahani S, et al.: Comparison of different approaches for assessment of HER2 expression on protein and mRNA level: Prediction of chemotherapy response in the neoadjuvant GeparTrio trial (NCT00544765). Breast Cancer Res Treat 126:109-117, 2011
9. Walker RA, Bartlett JM, Dowsett M, et al.: HER2 testing in the UK: Further update to recommendations. J Clin Path 61:818-824, 2008 (Pubitemid 351969725)
10. Moelans CB, de Weger RA, van Blokland MTM, et al.: HER-2/neu amplification testing in breast cancer by multiplex ligation-dependent probe amplification in comparison with immunohistochemistry and in situ hybridization. Cell Oncol 31:1-10, 2009
11. Genomic Health: Oncotype DX breast cancer assay: Quantitative singlegene scores. http://www.oncotypedx.com/en-US/Breast/HealthcareProfessional/ QuanitativeScores.aspx
12. Bartlett J, Mallon E, Cooke T: The clinical evaluation of HER-2 status: Which test to use? J Pathol 199:411-417, 2003 (Pubitemid 36411216)
13. Bartlett JM, Going JJ, Mallon EA, et al.: Evaluating HER2 amplification and overexpression in breast cancer. J Pathol 195:422-428, 2001 (Pubitemid 33069666)
14. Bartlett JM, Ibrahim M, Jasani B, et al.: External quality assurance of HER2 fluorescence in situ hybridisation testing: Results of a UK NEQAS pilot scheme. J Clin Path 60:816-819, 2007 (Pubitemid 47056913)
15. Bartlett JM, Ibrahim M, Jasani B, et al.: External quality assurance of HER2 FISH and ISH testing: Three years of the UK national external quality assurance scheme. Am J Clin Pathol 131:106-111, 2009
16. Bartlett JM: Biomarkers and patient selection for PI3K/Akt/mTOR targeted therapies: Current status and future directions. Clin Breast Cancer 10:S86-S95, 2010